VTGN · Vistagen Therapeutics, Inc. · Debt
$0.17
0.00 (-2.76%)
At close · Oct 28
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash, cash equivalents, and marketable securities of approximately $31.7 million. As of August 14, 2026, the issuance date of the condensed consolidated financial statements in this Quarterly Report as of and for the three months ended June 30, 2026, there is uncertainty about whether our combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the condensed consolidated financial statements in this Report and therefore we concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.46M
Shares
44.38M
Volume · Oct 28
743.09K
Avg daily vol (3M)
12.17M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 720,000 | 10-Q filed 2026-08-14 |
| Current portion of notes payable | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 63,000 | 10-Q filed 2026-08-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.